Send to

Choose Destination
J Dtsch Dermatol Ges. 2019 May;17(5):488-491. doi: 10.1111/ddg.13809. Epub 2019 Mar 15.

Management of dupilumab-associated conjunctivitis in atopic dermatitis.

Author information

Department of Dermatology and Allergology, University Medical Center, Munich, Germany.
Department of Ophthalmology at Mathildenstraße, University Medical Center, Munich, Germany.
Munich City Medical Center, Thalkirchner Straße, Munich, Germany.
Department of Dermatology and Allergology, University Medical Center, Utrecht, The Netherlands.


Since September 2017, the monoclonal antibody dupilumab (Dupixent® ) has been approved in the EU for the treatment of moderate-to-severe atopic dermatitis. By blocking IL-4 and IL-13 signaling pathways, dupilumab improves both objective signs and subjective symptoms of the disease. Blocking of the IL-4aRα subunit leads to improvement of the skin's barrier function and reduction in Th2-mediated inflammation. While the rate of adverse events on dupilumab is generally low, mild-to-moderate conjunctivitis associated with redness as well as a burning and foreign body sensation has been reported in up to 28 % of patients. Treatment options include topical corticosteroids and topical calcineurin inhibitors. The present review highlights the clinical presentation of dupilumab-associated conjunctivitis and addresses pharmacological and non-pharmacological options available for the treatment of this clinically highly relevant condition.


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center